Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, China.
Department of Oncology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, 530199, China.
World J Surg Oncol. 2024 Jul 11;22(1):180. doi: 10.1186/s12957-024-03460-z.
To address this evidence gap and validate short-term OS at less than 5 years as a reliable surrogate endpoint for 5-year OS.
We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on non-metastatic NPC patients diagnosed between 2010 and 2015. Patients were categorized into radiotherapy and chemoradiotherapy groups.
This retrospective study examined 2,047 non-metastatic NPC patients. Among them, 217 received radiotherapy, and 1,830 received chemoradiotherapy. Our analysis results indicated that the 4-year OS may serve as a reliable surrogate endpoint for patients with AJCC clinical stage I (80 vs. 78%, P = 0.250), regardless of the treatment received. Specifically, in the radiotherapy group, patients with stage I, T0-T1, and N0 NPC showed similar OS rates at 4 and 5 years (83 vs. 82%, P = 1.000; 78 vs. 76%, P = 0.250; 78 vs. 77%, P = 0.500, respectively). Similarly, patients with stage II-IV, T2-T4, and N1-3 NPC showed no significant difference in OS rates between 3 and 5 years (57 vs. 51%, P = 0.063; 52 vs. 46%, P = 0.250; 54 vs. 46%, P = 0.125, respectively) in the radiotherapy group. In the chemoradiotherapy group, only the 3-year OS rate did not significantly differ from that at 5 years in stage I patients (79vs. 72%, P = 0.063).
Our study suggests that short-term surrogate endpoints may be valuable for evaluating 5-year OS outcomes in NPC patients in non-endemic areas.
为了解决这一证据空白，我们验证了 5 年以下的短期总生存期（OS）作为 5 年 OS 的可靠替代终点。
我们分析了来自监测、流行病学和最终结果（SEER）数据库的数据，重点关注 2010 年至 2015 年间诊断的非转移性 NPC 患者。患者分为放疗和放化疗组。
这项回顾性研究共纳入了 2047 名非转移性 NPC 患者。其中，217 例接受放疗，1830 例接受放化疗。我们的分析结果表明，4 年 OS 可作为 AJCC 临床分期 I 期患者（80%与 78%，P=0.250）的可靠替代终点，无论接受何种治疗。具体来说，在放疗组中，I 期 T0-T1 和 N0 NPC 患者的 4 年和 5 年 OS 率相似（83%与 82%，P=1.000；78%与 76%，P=0.250；78%与 77%，P=0.500）。同样，在放疗组中，II-IV 期 T2-T4 和 N1-3 NPC 患者的 3 年和 5 年 OS 率无显著差异（57%与 51%，P=0.063；52%与 46%，P=0.250；54%与 46%，P=0.125）。在放化疗组中，只有 I 期患者的 3 年 OS 率与 5 年 OS 率无显著差异（79%与 72%，P=0.063）。
本研究表明，短期替代终点可能对评估非高发地区 NPC 患者的 5 年 OS 结局有价值。
